Insider Trading Alert: Anthera Pharmaceuticals, Inc. $ANTH

7c61d184c1c398afee8a007492657057

Anthera Pharmaceuticals, Inc. (ANTH) insider have most recently took part in a trading activity. On Sep 20, 2017 Thompson John Craig, President & CEO bought 8,550 shares having total worth of $11,286 at the price of $1.32 per share, following the transaction a total of 19,848 shares owned by Thompson John Craig. Before this latest buy, Thompson John Craig purchased ANTH at 1 other times during the past twelve months, for a total investment of $14,872 at an average of $1.43 per share.

The stock has experienced a total of 2 insider trades in the past three months. These trades include 2 buy trades. Furthermore, over the past 12 months , the stock was traded 2 times by insiders. an employee of the company was the buyer in 2 instances.

Time Frame Number of Insider Buy Number of Insider Sell Stock Price Change(%)
3 Month 2 0 -43.36%
12 Month 2 0 -95.42%

Shares of Anthera Pharmaceuticals, Inc. (ANTH) traded down 3.03% on Sep 19, 2017, hitting $1.28. 341,414 shares of the company’s stock traded hands. Anthera Pharmaceuticals, Inc. has a 52 week low of $1.23 and a 52 week high of $34.48. The company’s market cap is $135 million.

Anthera Pharmaceuticals, Inc. (ANTH) last announced its earnings results on Aug 9, 2017. The company reported -0.86 earnings per share (EPS) for the quarter, higher than the consensus estimate of -1.09 by $0.23. During the same quarter in the previous year, the company posted -0.35 earnings per share.

2017-08-09 2016-11-04 2016-05-09 2016-03-10 2015-11-06 2015-08-10 2015-05-11 2015-03-16 2014-11-14 2014-07-01
earnings per share -0.86 -0.61 -0.29 -0.18 -0.29 -0.25 -0.28 -0.32 -0.31 -0.34
Revenue(M) 0 0 0.15 1.92 0.73 0.29 0.25 0 0 12.8

Anthera Pharmaceuticals, Inc. was incorporated on September 9, 2004 in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing therapeutics to treat serious diseases associated with inflammation and autoimmune diseases. The Company’s primary product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, IgA nephropathy, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others. Government authorities in the United States at the federal, state and local level and other countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing, export and import of products such as those we are developing. The Company’s product candidate must be approved by the FDA through the new drug application, or NDA, process, and its biological product candidate, blisibimod, must be approved by the FDA through the biologics license application, or BLA, process before they may legally be marketed in the United States. The Company’s industry is highly competitive and subject to rapid and significant technological change. Its potential competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and research institutions.

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.